Abstract
The aim of this study was to evaluate the recently developed PANArray™ Human papilloma virus (HPV) kit for detection and genotyping of 19 high-risk and 13 low-risk HPV types, and compare it with the commercially available DNA chip kit genotyping of 24 HPVs. We collected cervical swabs from 741 patients with various stages of invasive cervical carcinoma being treated at the Samsung Medical Center. The overall HPV positivity rate was 73% using PANArrayTM HPV and 72.1% with the DNA chip, and no statistically significant differences were found with respect to the cytology grade. Comparing the results of the two chips, concordant results were found in 637/741 samples (85.9%), compatible in 69/741 (9.3%) and discordant in 35/741 (4.7%). Type-specific sequencing analysis of all samples revealed a 99.7% confirmation of PANArrayTM HPV genotyping results, compared to 91.0% of DNA chip. The PANArrayTM HPV test thus proved to be highly sensitive and accurate even when multiple HPV infections were present.
Similar content being viewed by others
References
Huang, S. et al. Principles and analytical performance of abbott real time high risk HPV test. J. Clin. Virol. 45Suppl 1, S13–17 (2009).
Huang, S. et al. Clinical performance of abbott real time high risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45Suppl 1, S19–23 (2009).
Schenk, T. et al. Performance of a polymer-based DNA chip platform in detection and genotyping of human papillomavirus in clinical samples. J. Clin. Microbiol. 47, 1428–1435 (2009).
Cuzick, J. et al. Overview of human papillomavirusbased and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26Suppl 10, K29–41 (2008).
Guo, M. et al. Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results. Mod. Pathol. 21, 1037–1043 (2008).
Huh, W., Einstein, M.H., Herzog, T.J. & Franco, E.L. What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol. Oncol. 117, 481–485 (2010).
Jones, J., Powell, N.G., Tristram, A., Fiander, A.N. & Hibbitts, S. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J. Clin. Virol. 45, 100–104 (2009).
Choi, J.J., Kim, C. & Park, H. Peptide nucleic acidbased array for detecting and genotyping human papillomaviruses. J. Clin. Microbiol. 47, 1785–1790 (2009).
Molijn, A., Kleter, B., Quint, W. & van Doorn, L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32 Suppl 1, S43–51 (2005).
Bae, J.H., Kim, C.J., Park, T.C., Namkoong, S.E. & Park, J.S. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int. J. Gynecol. Cancer 17, 1271–1277 (2007).
Cho, N.H. et al. Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis. Am. J. Obstet. Gynecol. 188, 56–62 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, H.J., Lee, J.W., Kim, B.G. et al. Comparison of the performance of the PANArray™ HPV test and DNA chip test for genotyping of human papillomavirus in cervical swabs. BioChip J 4, 167–172 (2010). https://doi.org/10.1007/s13206-010-4301-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13206-010-4301-y